Chemometec pursues cell therapy companies with tailored instrument

Chemometec's newest cell analysis instrument, which was launched in January, spearheads the company's all-important strategy to deliver instruments to biotech companies involved in cell therapy. Analyst points out the company as a potential acquisition target.

Photo: Kevin Grønnemann/MedWatch

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles